Our most-read articles explore “occlusion MI” versus STEMI, TAVI in asymptomatic AS, and highlights from recent conferences.

The lower rate of net adverse clinical events was driven by less bleeding in those on 1 month of prasugrel-based DAPT.

Researchers say the data further support the use of an FFR-first strategy in treating intermediate coronary lesions.